Pei Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pei Wu has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Huaizhang Shi
Department of Neurosurgery, The First Affiliated Hospital, Harbin Medical University, China
13 shared publications Qiaowei Wu
Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, Harbin, China
7 shared publicationsShancai Xu
Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, Harbin, China
7 shared publicationsChunlei Wang
Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
6 shared publicationsZhiyong Ji
Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
6 shared publicationsJingtao Qi
Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
5 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by Springer Nature in Microsystems & Nanoengineering
- Vol. 11 (1) , 247
NeuroDepth: an ultra long whole brain reachable multi-channel probe for real-time precise functional localization of deep human brain tumor margins
Precise intraoperative delineation of deep glioma margins remains challenging, as existing imaging modalities are limited by brain shift, poor penetration depth, or low spatial resolution, thus compromising surgical accuracy. Electrophysiological differences between tumor and normal tissues offer potential biomarkers, but lack high-resolution in vivo validation. We developed NeuroDepth, a tungsten-based multi-channel microelectrode array. With an implantation depth of up to 9 cm and 8 recording sites, the probe provides whole-brain accessibility. Its 15 µm diameter recording sites enable single-cell spatial resolution, while a 30 kHz sampling rate ensures high temporal fidelity for real-time signal acquisition. In this study, NeuroDepth was applied intraoperatively for the first time to monitor deep human glioma tissue. Spatial electrophysiological heterogeneity and longitudinal path-dependent variations revealed electrophysiological markers distinguishing tumor versus normal tissues. Compared with normal cortical surface recordings, glioma regions exhibited elevated neuronal firing rates, altered spike morphologies, and enhanced local field potential synchrony. Neuronal avalanche analysis revealed aberrant criticality within glioma tissue, suggesting unique dynamic network properties useful for boundary detection. A longitudinal recording along the cortex-white matter-tumor trajectory identified a characteristic "rebound" in neuronal activity upon entering the tumor, providing a clear demarcation signature. NeuroDepth demonstrates a new paradigm for intraoperative guidance, leveraging real-time electrophysiological detection to map deep tumor margins at a quantifiable single-cell resolution. It emerges as a promising tool to enhance resection accuracy while protecting functional brain areas.
- 11 December 2025
- Published by Springer Nature in Microsystems & Nanoengineering
- Vol. 11 (1) , 247
Open AccessNeuroDepth: an ultra long whole brain reachable multi-channel probe for real-time precise functional localization of deep human brain tumor margins
Precise intraoperative delineation of deep glioma margins remains challenging, as existing imaging modalities are limited by brain shift, poor penetration depth, or low spatial resolution, thus compromising surgical accuracy. Electrophysiological differences between tumor and normal tissues offer potential biomarkers, but lack high-resolution in vivo validation. We developed NeuroDepth, a tungsten-based multi-channel microelectrode array. With an implantation depth of up to 9 cm and 8 recording sites, the probe provides whole-brain accessibility. Its 15 µm diameter recording sites enable single-cell spatial resolution, while a 30 kHz sampling rate ensures high temporal fidelity for real-time signal acquisition. In this study, NeuroDepth was applied intraoperatively for the first time to monitor deep human glioma tissue. Spatial electrophysiological heterogeneity and longitudinal path-dependent variations revealed electrophysiological markers distinguishing tumor versus normal tissues. Compared with normal cortical surface recordings, glioma regions exhibited elevated neuronal firing rates, altered spike morphologies, and enhanced local field potential synchrony. Neuronal avalanche analysis revealed aberrant criticality within glioma tissue, suggesting unique dynamic network properties useful for boundary detection. A longitudinal recording along the cortex-white matter-tumor trajectory identified a characteristic "rebound" in neuronal activity upon entering the tumor, providing a clear demarcation signature. NeuroDepth demonstrates a new paradigm for intraoperative guidance, leveraging real-time electrophysiological detection to map deep tumor margins at a quantifiable single-cell resolution. It emerges as a promising tool to enhance resection accuracy while protecting functional brain areas.
- Open Access
- 23 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (33) , e08120
Advanced Brain‐on‐a‐Chip for Wetware Computing: A Review
In pursuit of low‐power consumption and surpassing computational limitations of silicon‐based chips, people are beginning to seek more efficient computing devices, such as Wetware Computing. The cutting‐edge approach uses living biological tissues, specifically neuronal networks, to perform computational tasks. This computing method, which is a mixture of hardware, software, and biology, is an emerging computing method that has received a lot of attention in recent years. As an important branch of organ‐on‐a‐chip, brain‐on‐a‐chip, which combines Micro‐Electro‐Mechanical System technology, electronic technology, and tissue engineering, can provide a powerful research platform for Wetware Computing. In this paper, the brain‐on‐a‐chip for Wetware Computing is reviewed. This paper summarizes the methods for establishing a brain‐on‐a‐chip for Wetware Computing, including the brain organoids cultured in vitro, microelectrode arrays, electrophysiology interfaces, and microfluidic platforms that make up the brain‐on‐a‐chip. In addition, the data processing methods of brain‐on‐a‐chip are reviewed, including encoding and decoding methods. In this paper, the focus is also on the application and the prospect of brain‐on‐a‐chip in Wetware Computing.
- 23 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (33) , e08120
Open AccessAdvanced Brain‐on‐a‐Chip for Wetware Computing: A Review
In pursuit of low‐power consumption and surpassing computational limitations of silicon‐based chips, people are beginning to seek more efficient computing devices, such as Wetware Computing. The cutting‐edge approach uses living biological tissues, specifically neuronal networks, to perform computational tasks. This computing method, which is a mixture of hardware, software, and biology, is an emerging computing method that has received a lot of attention in recent years. As an important branch of organ‐on‐a‐chip, brain‐on‐a‐chip, which combines Micro‐Electro‐Mechanical System technology, electronic technology, and tissue engineering, can provide a powerful research platform for Wetware Computing. In this paper, the brain‐on‐a‐chip for Wetware Computing is reviewed. This paper summarizes the methods for establishing a brain‐on‐a‐chip for Wetware Computing, including the brain organoids cultured in vitro, microelectrode arrays, electrophysiology interfaces, and microfluidic platforms that make up the brain‐on‐a‐chip. In addition, the data processing methods of brain‐on‐a‐chip are reviewed, including encoding and decoding methods. In this paper, the focus is also on the application and the prospect of brain‐on‐a‐chip in Wetware Computing.
- Open Access
- 6 January 2025
- Published by Elsevier in World Neurosurgery
- Vol. 194, 123569
Effect of Intravenous Alteplase Before Endovascular Thrombectomy on Outcome After Unsuccessful Recanalization in the DIRECT-MT Trial
- 6 January 2025
- Published by Elsevier in World Neurosurgery
- Vol. 194, 123569
Open AccessEffect of Intravenous Alteplase Before Endovascular Thrombectomy on Outcome After Unsuccessful Recanalization in the DIRECT-MT Trial
- Open Access
- 31 December 2024
- Published by Elsevier in Brain Research Bulletin
- Vol. 220, 111183
Bindarit attenuates neuroinflammation after subarachnoid hemorrhage by regulating the CCL2/CCR2/NF-κB pathway
- 31 December 2024
- Published by Elsevier in Brain Research Bulletin
- Vol. 220, 111183
Open AccessBindarit attenuates neuroinflammation after subarachnoid hemorrhage by regulating the CCL2/CCR2/NF-κB pathway
- Open Access
- 4 October 2024
- Published by Elsevier in World Neurosurgery
- Vol. 193, 1089-1098
Endovascular Treatment for Ruptured Intracranial Posterior Circulation Aneurysms: Complications and Clinical Outcomes
- 4 October 2024
- Published by Elsevier in World Neurosurgery
- Vol. 193, 1089-1098
Open AccessEndovascular Treatment for Ruptured Intracranial Posterior Circulation Aneurysms: Complications and Clinical Outcomes
- 12 July 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-9
Microsurgical clipping versus endovascular therapy for treating patients with middle cerebral artery aneurysms presenting with neurological ischemic symptoms
Studies comparing different treatment methods in patients with middle cerebral artery (MCA) aneurysms in different subgroups of onset symptoms are lacking. It is necessary to explore the safety and efficacy of open surgical treatment and endovascular therapy in patients with MCA aneurysms in a specific population. This study aimed to compare microsurgical clipping versus endovascular therapy regarding complication rates and outcomes in patients with MCA aneurysms presenting with neurological ischemic symptoms. This was a retrospective cohort study in which 9656 patients with intracranial aneurysms were screened between January 2014 and July 2022. Further, 130 eligible patients were enrolled. The primary outcome was the incidence of serious adverse events (SAEs) within 30 days of treatment, whereas secondary outcomes included postprocedural target vessel–related stroke, disabling stroke or death, mortality, and aneurysm occlusion rate. Among the 130 included patients, 45 were treated with endovascular therapy and 85 with microsurgical clipping. The primary outcome of the incidence of SAEs within 30 days of treatment was significantly higher in the clipping group [clipping: 23.5%(20/85) vs endovascular: 8.9%(4/45), adjusted OR:4.05, 95% CI:1.20–13.70; P = 0.024]. The incidence of any neurological complications related to the treatment was significantly higher in the clipping group [clipping:32.9%(28/85) vs endovascular:15.6%(7/45); adjusted OR:3.49, 95%CI:1.18–10.26; P = 0.023]. Postprocedural target vessel–related stroke, disabling stroke or death, mortality rate, and complete occlusion rate did not differ significantly between the two groups. Endovascular therapy seemed to be safer in treating patients with MCA aneurysms presenting with neurological ischemic symptoms compared with microsurgical clipping, with a significantly lower incidence of SAEs within 30 days of treatment and any neurological complications related to the treatment during follow-up.
- 12 July 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-9
Microsurgical clipping versus endovascular therapy for treating patients with middle cerebral artery aneurysms presenting with neurological ischemic symptoms
Studies comparing different treatment methods in patients with middle cerebral artery (MCA) aneurysms in different subgroups of onset symptoms are lacking. It is necessary to explore the safety and efficacy of open surgical treatment and endovascular therapy in patients with MCA aneurysms in a specific population. This study aimed to compare microsurgical clipping versus endovascular therapy regarding complication rates and outcomes in patients with MCA aneurysms presenting with neurological ischemic symptoms. This was a retrospective cohort study in which 9656 patients with intracranial aneurysms were screened between January 2014 and July 2022. Further, 130 eligible patients were enrolled. The primary outcome was the incidence of serious adverse events (SAEs) within 30 days of treatment, whereas secondary outcomes included postprocedural target vessel–related stroke, disabling stroke or death, mortality, and aneurysm occlusion rate. Among the 130 included patients, 45 were treated with endovascular therapy and 85 with microsurgical clipping. The primary outcome of the incidence of SAEs within 30 days of treatment was significantly higher in the clipping group [clipping: 23.5%(20/85) vs endovascular: 8.9%(4/45), adjusted OR:4.05, 95% CI:1.20–13.70; P = 0.024]. The incidence of any neurological complications related to the treatment was significantly higher in the clipping group [clipping:32.9%(28/85) vs endovascular:15.6%(7/45); adjusted OR:3.49, 95%CI:1.18–10.26; P = 0.023]. Postprocedural target vessel–related stroke, disabling stroke or death, mortality rate, and complete occlusion rate did not differ significantly between the two groups. Endovascular therapy seemed to be safer in treating patients with MCA aneurysms presenting with neurological ischemic symptoms compared with microsurgical clipping, with a significantly lower incidence of SAEs within 30 days of treatment and any neurological complications related to the treatment during follow-up.
- 10 April 2024
- Published by Elsevier in Experimental Neurology
- Vol. 376, 114776
LAMC1 attenuates neuronal apoptosis via FAK/PI3K/AKT signaling pathway after subarachnoid hemorrhage
- 10 April 2024
- Published by Elsevier in Experimental Neurology
- Vol. 376, 114776
LAMC1 attenuates neuronal apoptosis via FAK/PI3K/AKT signaling pathway after subarachnoid hemorrhage
- Open Access
- 1 June 2023
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 13 (6) , 3536-3546
Low-profile visualized intraluminal support-within-Enterprise overlapping-stent technique versus flow diversion in the treatment of intracranial vertebrobasilar trunk dissecting aneurysms
Original Article Low-profile visualized intraluminal support-within-Enterprise overlapping-stent technique versus flow diversion in the treatment of intracranial vertebrobasilar trunk dissecting aneurysms Qiaowei Wu, Chunlei Wang, Shancai Xu, Zhiyong Ji, Jingtao Qi, Yuchen Li, Jinbiao Yao, Huaizhang Shi, Pei Wu
- 1 June 2023
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 13 (6) , 3536-3546
Open AccessLow-profile visualized intraluminal support-within-Enterprise overlapping-stent technique versus flow diversion in the treatment of intracranial vertebrobasilar trunk dissecting aneurysms
Original Article Low-profile visualized intraluminal support-within-Enterprise overlapping-stent technique versus flow diversion in the treatment of intracranial vertebrobasilar trunk dissecting aneurysms Qiaowei Wu, Chunlei Wang, Shancai Xu, Zhiyong Ji, Jingtao Qi, Yuchen Li, Jinbiao Yao, Huaizhang Shi, Pei Wu
- Open Access
- 24 March 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14
LVIS-within-enterprise double-stent technique with coil embolization in the treatment of patients with acutely ruptured intracranial vertebrobasilar artery-dissecting aneurysms
Objective: This study aimed to evaluate the feasibility of the low-profile visualized intraluminal support (LVIS)-within-enterprise double-stent technique for patients with acutely ruptured intracranial vertebrobasilar artery-dissecting aneurysms (ari-VBDAs).Methods: A total of 30 patients with ari-VBDAs who underwent reconstructive treatment using LVIS-within-enterprise double-stent technique with coil embolization between January 2014 and May 2022 were retrospectively enrolled. Patients' characteristics and clinical and imaging outcomes were reviewed. The functional outcomes were assessed using the modified Rankin scale (mRS).Results: A total of 34 ari-VBDAs were identified, including seven (20.6%) basilar artery aneurysms and 27 (79.4%) vertebral artery aneurysms. All aneurysms were successfully treated in the acute phase. In total, six (20.0%) patients experienced in-hospital serious adverse events, including two deaths (6.7%). The median clinical follow-up time of the remaining 28 patients was 20.0 (IQR, 7.3–40.8) months. The incidences of dependency or death (mRS score of 3–6) at discharge and at the last follow-up were 16.7% and 14.3%, respectively. Aneurysm rebleeding occurred in one (3.3%) patient periprocedurally. In total, three (10.0%) patients had ischemic events, one of which occurred during the periprocedural period and two occurred during follow-up. A total of two patients (6.7%) underwent ventriculoperitoneal shunt. Imaging follow-up was available for 14 patients at the median of 12.0 (IQR, 7.0–12.3) months, with a complete occlusion rate of 93.3% (14/15). In total, one patient experienced parent artery occlusion, and no aneurysm was recanalized.Conclusion: LVIS-within-enterprise double-stent technique with coil embolization for the treatment of patients with ari-VBDAs could be performed with a good safety profile and high technical success rate. The rate of complete aneurysm occlusion during follow-up seemed to be satisfactory.
- 24 March 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14
Open AccessLVIS-within-enterprise double-stent technique with coil embolization in the treatment of patients with acutely ruptured intracranial vertebrobasilar artery-dissecting aneurysms
Objective: This study aimed to evaluate the feasibility of the low-profile visualized intraluminal support (LVIS)-within-enterprise double-stent technique for patients with acutely ruptured intracranial vertebrobasilar artery-dissecting aneurysms (ari-VBDAs).Methods: A total of 30 patients with ari-VBDAs who underwent reconstructive treatment using LVIS-within-enterprise double-stent technique with coil embolization between January 2014 and May 2022 were retrospectively enrolled. Patients' characteristics and clinical and imaging outcomes were reviewed. The functional outcomes were assessed using the modified Rankin scale (mRS).Results: A total of 34 ari-VBDAs were identified, including seven (20.6%) basilar artery aneurysms and 27 (79.4%) vertebral artery aneurysms. All aneurysms were successfully treated in the acute phase. In total, six (20.0%) patients experienced in-hospital serious adverse events, including two deaths (6.7%). The median clinical follow-up time of the remaining 28 patients was 20.0 (IQR, 7.3–40.8) months. The incidences of dependency or death (mRS score of 3–6) at discharge and at the last follow-up were 16.7% and 14.3%, respectively. Aneurysm rebleeding occurred in one (3.3%) patient periprocedurally. In total, three (10.0%) patients had ischemic events, one of which occurred during the periprocedural period and two occurred during follow-up. A total of two patients (6.7%) underwent ventriculoperitoneal shunt. Imaging follow-up was available for 14 patients at the median of 12.0 (IQR, 7.0–12.3) months, with a complete occlusion rate of 93.3% (14/15). In total, one patient experienced parent artery occlusion, and no aneurysm was recanalized.Conclusion: LVIS-within-enterprise double-stent technique with coil embolization for the treatment of patients with ari-VBDAs could be performed with a good safety profile and high technical success rate. The rate of complete aneurysm occlusion during follow-up seemed to be satisfactory.